Trastuzumab/hyaluronidase
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Trastuzumab/hyaluronidase?
Summarize this article for a 10 year old
Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast cancer in adults.[1][2] It is a combination of trastuzumab and hyaluronidase.[1][2][3]
Combination of | |
---|---|
Trastuzumab | HER2/neu receptor antagonist |
Hyaluronidase | Endoglycosidase |
Clinical data | |
Trade names | Herceptin SC, Herceptin Hylecta |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a619041 |
Routes of administration | Subcutaneous injection |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
UNII | |
KEGG |
The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction, upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity.[1][2]
Trastuzumab/hyaluronidase was approved for medical use in the European Union in August 2013.[4] Trastuzumab/hyaluronidase was approved for medical use in the United States in February 2019.[1][5][6][7][8]